ABC Transporters and Resistance to Antibiotics

Michalet, Serge; Dijoux‐Franca, Marie‐Geneviève

doi:10.1002/9780470495131.ch6

Cited by 1 publication

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multi-Drug Resistance is a collective term for efflux mechanisms that allow chemotherapy drugs to be pumped out of the cell before DNA damage can occur [ 59 ]. The best characterised MDR proteins are the members of the ‘ABC (ATP-Binding Cassette) transporter’ family, which were originally described in bacterial anti-biotic resistance [ 60 ]. It was subsequently found that many cell types possess ABC transporters.…”

Section: Cscs Employ a Collection Of Therapy-resistance Mechanismsmentioning

confidence: 99%

Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention

et al. 2017

View full text Add to dashboard Cite

It is widely believed that targeting the tumour-initiating cancer stem cell (CSC) component of malignancy has great therapeutic potential, particularly in therapy-resistant disease. However, despite concerted efforts, CSC-targeting strategies have not been efficiently translated to the clinic. This is partly due to our incomplete understanding of the mechanisms underlying CSC therapy-resistance. In particular, the relationship between therapy-resistance and the organisation of CSCs as Stem-Progenitor-Differentiated cell hierarchies has not been widely studied. In this review we argue that modern clinical strategies should appreciate that the CSC hierarchy is a dynamic target that contains sensitive and resistant components and expresses a collection of therapy-resisting mechanisms. We propose that the CSC hierarchy at primary presentation changes in response to clinical intervention, resulting in a recurrent malignancy that should be targeted differently. As such, addressing the hierarchical organisation of CSCs into our bench-side theory should expedite translation of CSC-targeting to bed-side practice. In conclusion, we discuss strategies through which we can catch these moving clinical targets to specifically compromise therapy-resistant disease.

show abstract

Section: Cscs Employ a Collection Of Therapy-resistance Mechanismsmentioning

confidence: 99%